| Title |
Clinical Pharmacology and Cardiovascular Safety of Naproxen
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, November 2016
|
| DOI | 10.1007/s40256-016-0200-5 |
| Pubmed ID | |
| Authors |
Dominick J. Angiolillo, Steven M. Weisman |
| Abstract |
The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2 selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs. The over-the-counter (OTC) use of naproxen is expected to pose minimal cardiovascular risk; however, the benefit-risk ratio and appropriate use should be considered at an individual patient level, particularly to assess underlying conditions that may increase the risk of events. Likewise, regulatory authorities should revisit label information periodically to ensure labeling reflects the current understanding of benefits and risks. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 196 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 196 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 30 | 15% |
| Student > Master | 25 | 13% |
| Student > Ph. D. Student | 12 | 6% |
| Other | 11 | 6% |
| Researcher | 11 | 6% |
| Other | 25 | 13% |
| Unknown | 82 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 15% |
| Medicine and Dentistry | 24 | 12% |
| Nursing and Health Professions | 12 | 6% |
| Chemistry | 11 | 6% |
| Biochemistry, Genetics and Molecular Biology | 9 | 5% |
| Other | 24 | 12% |
| Unknown | 87 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2023.
All research outputs
#6,204,195
of 25,202,494 outputs
Outputs from American Journal of Cardiovascular Drugs
#133
of 464 outputs
Outputs of similar age
#86,776
of 320,078 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#2
of 6 outputs
Altmetric has tracked 25,202,494 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 464 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,078 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.